Full Description
Dear Reader,
2024 saw a significant shift towards the use of AI and data analytics for pharmaceutical advertising. This then drives the need for increased regulation on a global scale due to the digital opportunities available to reach healthcare professionals, the general public and healthcare stakeholders. Key trends across the globe include stricter checks on biosimilars, a growing emphasis on sustainability, and transparency and disclosure gaining more importance. Whichever direction jurisdictions are heading, there is no doubt that the geopolitical environment and ensuing trade deals will have huge effects for organisations within this practice area, which then leads to even more diligence being required from legal professionals in this space.
The publication - now in its 22nd edition - sets out to cover practical questions within the pharmaceutical advertising law topic across 19 jurisdictions, providing indispensable information from leading legal minds for the benefit of you, the Readers. There is also a deep dive through the Expert Analysis contributions from Arnold & Porter into disparagement in competition law and from Ropes & Gray LLP into evidence-based engagements and communications.
As always in this ever-developing area of law, 2025 is expecting to see big developments. Challenges around drug pricing and access, stricter legislation around influencer marketing and an increased focus on health literacy will all present challenges that legal professionals will be required to cope with. This publication has been written by leading pharmaceutical advertising lawyers and industry specialists, for whose invaluable contributions the editors and publishers are extremely grateful. I would also like to extend special thanks to contributing editor Adela Williams from Arnold & Porter for her leadership, support and expertise in bringing this project to fruition.
Contents
Expert Analysis Chapters
1 When Criticising Competitor Products Becomes an Antitrust Problem: Disparagement in Competition Law
John Schmidt & Zeno Frediani, Arnold & Porter
6 Evidence-Based Engagements and Communications in Response to an Ever-Changing External Environment
Lincoln Tsang, Kellie Combs & Katherine Wang, Ropes & Gray LLP
Q&A Chapters
13 Australia
Greg Williams & Sheena McKie, Clayton Utz
28 Austria
Dr. Sonja Hebenstreit, Herbst Kinsky Rechtsanwälte GmbH
43 Belgium
Olivier Van Obberghen, Pieter Wyckmans &
Michiel D'herde, Quinz
58 England & Wales
Adela Williams & Libby Amos-58 Stone, Arnold & Porter
75 Finland
Mikael Segercrantz, Johanna Lilja & Silva Peltola,
Roschier, Attorneys Ltd.
89 Germany
Dr. Peter Dieners & Marlene Kießling, Clifford Chance
109 Greece
Irene Kyriakides, Aithra Valentina Antoniadou,
Vicky Vlontzou & Anastasia Iliopoulou,
KYRIAKIDES GEORGOPOULOS Law Firm
125 Ireland
Colin Kavanagh, Orla Clayton, Bridget Clinton &
Robert Byrne, Arthur Cox LLP
141 Italy
Sonia Selletti & Annalisa Scalia,
Astolfi e Associati Studio Legale
157 Japan
Shinya Tago, Minako Ikeda & Landry Guesdon,
Iwata Godo
170 Korea
Hyeong Gun Lee, Eileen Jaiyoung Shin & Hyun Ah Song,
Lee & Ko
181 Mexico
Luz Elena Elias & Ingrid Ortiz, OLIVARES
193 Netherlands
Robbert Sjoerdsma & Annelotte Boot, Holla legal & tax
203 Romania
Bogdan Blaj, Brigitta Kedves, Csenge Fejér &
Zenkő Fábián, Blaj Law
216 Serbia
Rastko Mališić & Jelena Šuša Ranisavljević,
MMD Advokati
226 Sweden
Camilla Appelgren & Emmie Montgomery,
Mannheimer Swartling Advokatbyrå
239 Switzerland
Frank Scherrer & Ines Holderegger, Wenger Vieli Ltd.
253 Türkiye
Dr. Elvan Sevi Bozoğlu, Dr. Mehmet Feridun İzgi & Simge Kublay Can, Bozoğlu İzgi Attorney Partnership
263 USAe Kim, Christopher M. Mikson, Jianyuan Hua &Christine Michel Lentz, DLA Piper LLP
